| Drug Name |
Sitagliptin |
| Drug ID |
BADD_D02029 |
| Description |
Sitagliptin is an oral dipeptidyl peptidase-4 (DPP-4) inhibitor used in conjunction with diet and exercise to improve glycemic control in patients with type 2 diabetes mellitus[Label,A2260,A2255,A2256]. The effect of this medication leads to glucose dependent increases in insulin and decreases in glucagon to improve control of blood sugar[Label,A2255]. Sitagliptin was granted FDA approval on October 16, 2006[L6061]. |
| Indications and Usage |
For use as an adjunct to diet and exercise to improve glycemic control in patients with type 2 diabetes mellitus. Also for use in patients with type 2 diabetes mellitus to improve glycemic control in combination with metformin or a PPARγ agonist (e.g., thiazolidinediones) when the single agent alone, with diet and exercise, does not provide adequate glycemic control. |
| Marketing Status |
Prescription |
| ATC Code |
A10BH01 |
| DrugBank ID |
DB01261
|
| KEGG ID |
D08516
|
| MeSH ID |
D000068900
|
| PubChem ID |
4369359
|
| TTD Drug ID |
D0U2JP
|
| NDC Product Code |
55154-5042; 50090-3527; 0006-0221; 50090-3472; 0006-0112; 50090-4084; 50090-4087; 50090-5517; 50090-4086; 59285-042; 55154-5040; 50090-5547; 50090-5585; 0006-0277 |
| Synonyms |
Sitagliptin Phosphate | Phosphate, Sitagliptin | Sitagliptin Phosphate Monohydrate | Monohydrate, Sitagliptin Phosphate | Phosphate Monohydrate, Sitagliptin | Sitagliptin Monophosphate Monohydrate | Monohydrate, Sitagliptin Monophosphate | Monophosphate Monohydrate, Sitagliptin | MK 0431 | 0431, MK | MK0431 | MK-0431 | Sitagliptin Phosphate Anhydrous | Anhydrous, Sitagliptin Phosphate | Phosphate Anhydrous, Sitagliptin | Sitagliptin | 4-Oxo-4-(3-(trifluoromethyl)-5,6-dihydro(1,2,4)triazolo(4,3-a)pyrazin-7(8H)-yl)-1-(2,4,5-trifluorophenyl)butan-2-amine | Januvia |
